The Short Answer
One Receptor or Two
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors, two gut hormones that help regulate blood sugar and appetite.
Each Ingredient Has Diabetes and Weight Brands
Ozempic®, Rybelsus® and Mounjaro® are approved for type 2 diabetes. Wegovy® and Zepbound® are the brands whose labels include long-term weight reduction.
Two Trials Compared Them Directly
In adults with obesity, the SURMOUNT-5 trial found greater average weight loss with tirzepatide. In adults with type 2 diabetes, the SURPASS-2 trial on the Mounjaro® label found larger average drops in HbA1c and weight with tirzepatide.
Stomach Effects Lead Both
Nausea, diarrhea, vomiting and constipation are the most common side effects for both ingredients. They show up most while the dose is being raised.
Which Brands Contain Each Ingredient
Most confusion comes from brand names, not ingredients. Find your own medicine first.
| Brand | Ingredient | Maker | Form |
|---|---|---|---|
| Ozempic® | Semaglutide | Novo Nordisk | Once-weekly injection |
| Ozempic® tablets | Semaglutide | Novo Nordisk | Once-daily tablet |
| Rybelsus® | Semaglutide | Novo Nordisk | Once-daily tablet |
| Wegovy® | Semaglutide | Novo Nordisk | Once-weekly injection or once-daily tablet |
| Mounjaro® | Tirzepatide | Eli Lilly | Once-weekly injection |
| Zepbound® | Tirzepatide | Eli Lilly | Once-weekly injection |
Semaglutide for Type 2 Diabetes
Ozempic® is a once-weekly injection for adults with type 2 diabetes, and Ozempic® tablets are a once-daily option on a separate label. Rybelsus® is a once-daily semaglutide tablet that shares that tablet label.
The Ozempic® injection label also covers lowering heart and kidney risks in certain adults with type 2 diabetes. Both tablet brands are approved for blood sugar control and for heart event risk reduction in high-risk adults with type 2 diabetes.
Semaglutide for Weight Reduction
Wegovy® comes as a once-weekly injection or a once-daily tablet. Its label covers long-term weight reduction, heart event risk reduction in adults with heart disease and, for the injection, a liver condition called MASH.
Tirzepatide for Type 2 Diabetes
Mounjaro® is a once-weekly injection for blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to lower heart event risk in high-risk adults with type 2 diabetes.
Tirzepatide for Weight Reduction
Zepbound® is a once-weekly injection for long-term weight reduction in adults with obesity, or overweight with a weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity.
Brand-level comparisons: Ozempic® vs Wegovy®, Mounjaro® vs Ozempic® and Wegovy® vs Zepbound®.
Not Meant to Be Combined
The Wegovy® and Zepbound® labels both say using them with any other GLP-1 receptor agonist is not recommended. Tirzepatide and semaglutide are not taken together.
The Two Head-to-Head Trials
Two published trials put tirzepatide and semaglutide side by side. Every figure below is a group average from one trial.
| SURMOUNT-5 | SURPASS-2 | |
|---|---|---|
| Who was in it | 751 adults with obesity, without type 2 diabetes | 1,879 adults with type 2 diabetes taking metformin |
| What was compared | Tirzepatide vs semaglutide, highest tolerated dose, once weekly | Mounjaro® 5 mg, 10 mg or 15 mg vs semaglutide 1 mg, once weekly |
| Length | 72 weeks | 40 weeks |
| Average weight change | -20.2% vs -13.7% of body weight | -7.6 kg to -11.2 kg vs -5.7 kg |
| Average HbA1c change | Not applicable (no type 2 diabetes) | -2.0 to -2.3 points vs -1.9 points |
| Design | Open-label, funded by Eli Lilly | Open-label, funded by Eli Lilly |
SURMOUNT-5, in Adults With Obesity
SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to tirzepatide or semaglutide at the highest dose they could tolerate, once weekly for 72 weeks. Average weight fell by 20.2% on tirzepatide and 13.7% on semaglutide, as published in the New England Journal of Medicine in July 2025.
SURPASS-2, in Adults With Type 2 Diabetes
SURPASS-2 compared Mounjaro® 5 mg, 10 mg and 15 mg with semaglutide 1 mg for 40 weeks in 1,879 adults taking metformin. Average HbA1c fell by 2.0 to 2.3 points on Mounjaro® versus 1.9 on semaglutide, and average weight fell by 7.6 kg to 11.2 kg versus 5.7 kg.
What These Trials Leave Out
Both trials were open-label and funded by Eli Lilly, and SURPASS-2 used semaglutide 1 mg rather than the higher doses now on the labels. They report group averages, which cannot tell you how your own body will respond.
How to Use the Numbers
Bring the trial name and the averages to your prescriber as a starting point. Your health history, other medicines and coverage all shape the decision.
How the Dose Ladders Differ
These are the steps each FDA label lists, quoted from the labels so the numbers make sense. They are the labels' own schedules, not a recommendation or a plan for you.
Semaglutide Injections
The Ozempic® and Wegovy® injection labels both start at 0.25 mg once weekly and step up after 4 weeks at a time. The Ozempic® label tops out at 2 mg, and the Wegovy® label recommends 2.4 mg for adult weight maintenance, with 7.2 mg as a maximum for some adults.
Semaglutide Tablets
Wegovy® tablets and Ozempic® tablets both start at 1.5 mg once daily for 30 days, while Rybelsus® starts at 3 mg. Each tablet label has its own steps after that, and the Rybelsus® label says its tablets and Ozempic® tablets are not swapped milligram for milligram.
Tirzepatide Injections
The Mounjaro® and Zepbound® labels both start at 2.5 mg once weekly and increase in 2.5 mg steps after at least 4 weeks on each dose. Both list 15 mg as the adult maximum.
No Conversion Between Them
Milligram amounts of different molecules can't be compared, so a milligram of semaglutide says nothing about a milligram of tirzepatide. Your prescriber sets every step, and Pep AI never suggests a dose.
Side Effects Reported on the Labels
Side effects are a deciding worry for many readers. The weight-reduction trials on the Wegovy® and Zepbound® labels give the clearest like-for-like context available, read each against its own placebo.
| Side effect | Wegovy® 2.4 mg vs placebo | Zepbound® vs placebo |
|---|---|---|
| Nausea | 44% vs 16% | 25-29% vs 8% |
| Diarrhea | 30% vs 16% | 19-23% vs 8% |
| Vomiting | 24% vs 6% | 8-13% vs 2% |
| Constipation | 24% vs 11% | 11-17% vs 5% |
Reading the Two Columns
The two label tables come from separate trials with different people, doses and lengths, and both labels say rates from one drug's trials cannot be directly compared with another's. Zepbound® was tested at several maintenance doses, so its column shows the range across them.
What the Head-to-Head Trial Saw
In SURMOUNT-5, stomach effects were the most common side effects in both groups. Most were mild to moderate and happened mainly during dose increases.
Full Guides for Each Ingredient
The GLP-1 side effects guide sets out both labels' full tables and warning signs, and side effects by week covers when they tend to show up.
Track Either Ingredient in Pep AI
After your prescriber decides, the daily work starts. Pep AI handles every brand of both ingredients.
Every Brand in One Log
Pep AI logs a weekly Ozempic®, Wegovy®, Mounjaro® or Zepbound® shot, or a daily tablet with its own schedule. When your prescriber changes your dose, the new amount goes on the same history, so your current step is always clear.
Reminders That Fit Weekly or Daily
Pep AI reminds you on shot day or tablet day, and each medicine keeps its own schedule. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.
Symptoms, Day by Day
Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can tell your prescriber what started when. More in the side effects tracker.
A Report for Your Prescriber
Pep AI turns your doses, injection sites, weight and daily meal totals into a PDF report you can share with your prescriber. It gives your prescriber a clear record when you talk through the options.
Key takeaways
- Semaglutide (Ozempic®, Wegovy®, Rybelsus®) acts on GLP-1; tirzepatide (Mounjaro®, Zepbound®) acts on GIP and GLP-1.
- In SURMOUNT-5, average weight loss was larger with tirzepatide; in SURPASS-2, average HbA1c and weight drops were larger with tirzepatide. Both were open-label and Lilly-funded, and averages are not a promise for one person.
- Milligram amounts of different molecules can't be compared. There is no conversion between them.
- Nausea, diarrhea, vomiting and constipation lead both labels, mostly while the dose is being raised.
- Which medicine, which dose and any switch are decisions for you and your prescriber.
Whatever your prescriber decides, keep the record.
Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.
Frequently asked questions
Keep reading
Sources
- Ozempic® (semaglutide) injection prescribing information, Novo Nordisk / FDA (revised 05/2026)
- Rybelsus® and Ozempic® (semaglutide) tablets prescribing information, Novo Nordisk / FDA (revised 01/2026)
- Wegovy® (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
- Mounjaro® (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
- Zepbound® (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515
This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026